Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to assets ratio is N/A as of Tuesday, October 6, 2026.
DEBT TO ASSETS RATIO
N/A
Electra Therapeutics Inc.
Market Cap
$203.00M
Debt to Assets Ratio
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Electra Therapeutics Inc. (ETRA) | $203.00M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $196.44M | 0.00% |
| AN2 Therapeutics, Inc. (ANTX)vs › | $189.81M | 0.00% |
| Compugen Ltd. (CGEN)vs › | $217.47M | 0.02% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $220.71M | 0.12% |
| Journey Medical Corporation (DERM)vs › | $183.85M | 0.26% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.67M | 0.00% |
| Cue Biopharma, Inc. (CUE)vs › | $178.11M | 0.29% |
| Keros Therapeutics, Inc. (KROS)vs › | $228.61M | 0.05% |
| Alector, Inc. (ALEC)vs › | $231.49M | 0.16% |
Debt/Assets
N/A
Debt/Equity
N/A
Current Ratio
N/A
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
